BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...business development at its CARMA Cellular Therapies unit. Abbato was VP of business development at Celdara Medical LLC...
BioCentury | Oct 6, 2017
Clinical News

Celyad’s CAR T leads to leukemia-free state in AML patient

...receptor subfamily K member 1 (NKG2D; KLRK1; CD314). Celyad is developing CYAD-01 in partnership with Celdara Medical LLC...
...and Dartmouth College (Hanover, N.H.) under an amended 2015 deal (see BioCentury, Aug. 10 ). Celdara Medical LLC...
BioCentury | Aug 10, 2017
Company News

Celyad amends CAR T deal

...its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC...
...partially covers the cash portion of the amended Celdara deal (see BioCentury, May 8 ). Celdara Medical LLC...
...College , Hanover, N.H. Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Business: Gene/Cell therapy, Cancer Chris Lieu CAR-T NKR-2 Celdara Medical LLC Celyad...
BioCentury | Aug 4, 2017
Company News

Celyad gains on CAR T deal amendment

...its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC...
...the cash portion of the amended Celdara deal (see BioCentury Extra, May 2) . Chris Lieu CAR-T NKR-2 Celdara Medical LLC Celyad...
BioCentury | May 11, 2017
Translation in Brief

Going universal

...solid and hematological cancers. Formerly Cardio3 BioSciences S.A., Celyad began developing cancer immunotherapies after acquiring Celdara Medical LLC...
BioCentury | Feb 28, 2015
Financial News

Cardio3 raises EUR 31.7M

...chimeric antigen receptor (CAR) T therapies via its acquisition of Oncyte, the oncology division of Celdara Medical LLC...
BioCentury | Jan 20, 2014
Company News

Celdara Medical, Virtici, Daiichi Sankyo deal

...exclusive development. Daiichi and Celdara declined to disclose details, and Virtici could not be reached. Celdara Medical LLC...
BioCentury | Oct 24, 2013
Strategy

Driving CAR-based cellular therapies

...CAR deals include a partnership between the Geisel School of Medicine at Dartmouth College and Celdara Medical LLC...
...Abingdon, U.K. Baylor College of Medicine , Houston, Texas bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Celdara Medical LLC...
...but collaborations between gene therapy company Adaptimmune Ltd. and East Coast universities and between accelerator Celdara Medical LLC...
Items per page:
1 - 8 of 8
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...business development at its CARMA Cellular Therapies unit. Abbato was VP of business development at Celdara Medical LLC...
BioCentury | Oct 6, 2017
Clinical News

Celyad’s CAR T leads to leukemia-free state in AML patient

...receptor subfamily K member 1 (NKG2D; KLRK1; CD314). Celyad is developing CYAD-01 in partnership with Celdara Medical LLC...
...and Dartmouth College (Hanover, N.H.) under an amended 2015 deal (see BioCentury, Aug. 10 ). Celdara Medical LLC...
BioCentury | Aug 10, 2017
Company News

Celyad amends CAR T deal

...its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC...
...partially covers the cash portion of the amended Celdara deal (see BioCentury, May 8 ). Celdara Medical LLC...
...College , Hanover, N.H. Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Business: Gene/Cell therapy, Cancer Chris Lieu CAR-T NKR-2 Celdara Medical LLC Celyad...
BioCentury | Aug 4, 2017
Company News

Celyad gains on CAR T deal amendment

...its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC...
...the cash portion of the amended Celdara deal (see BioCentury Extra, May 2) . Chris Lieu CAR-T NKR-2 Celdara Medical LLC Celyad...
BioCentury | May 11, 2017
Translation in Brief

Going universal

...solid and hematological cancers. Formerly Cardio3 BioSciences S.A., Celyad began developing cancer immunotherapies after acquiring Celdara Medical LLC...
BioCentury | Feb 28, 2015
Financial News

Cardio3 raises EUR 31.7M

...chimeric antigen receptor (CAR) T therapies via its acquisition of Oncyte, the oncology division of Celdara Medical LLC...
BioCentury | Jan 20, 2014
Company News

Celdara Medical, Virtici, Daiichi Sankyo deal

...exclusive development. Daiichi and Celdara declined to disclose details, and Virtici could not be reached. Celdara Medical LLC...
BioCentury | Oct 24, 2013
Strategy

Driving CAR-based cellular therapies

...CAR deals include a partnership between the Geisel School of Medicine at Dartmouth College and Celdara Medical LLC...
...Abingdon, U.K. Baylor College of Medicine , Houston, Texas bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Celdara Medical LLC...
...but collaborations between gene therapy company Adaptimmune Ltd. and East Coast universities and between accelerator Celdara Medical LLC...
Items per page:
1 - 8 of 8